Questions About Cancer? 1-800-4-CANCER
NCI Cancer Center News

University of Arizona study finds cancer drug improves survival in patients with metastatic melanoma

  • Posted: November 14, 2012

Results of a University of Arizona Cancer Center’s scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in patients with metastatic melanoma. The findings of the Phase III study of nab-paclitaxel, brand name Abraxane®, therapy compared to standard dacarbazine therapy were presented at the Society for Melanoma Research in California Nov. 11.

Click here to read full press release.


NCI comprehensive cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.